
Monday, June 17, 2024 10:29:34 PM
Recent BPTH News
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 04/11/2025 08:28:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2025 08:13:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2025 12:47:40 PM
- Bio-Path Holdings Reports Full Year 2024 Financial Results • GlobeNewswire Inc. • 03/28/2025 11:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2025 08:42:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2025 11:15:19 AM
- Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients • GlobeNewswire Inc. • 03/18/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2025 10:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2025 12:00:28 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/14/2025 10:26:30 PM
- Bio-Path Holdings Expands Global Patent Portfolio • GlobeNewswire Inc. • 02/13/2025 09:01:54 PM
- Bio-Path Holdings Provides Key Clinical Updates • GlobeNewswire Inc. • 02/13/2025 01:00:00 PM
- Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia • GlobeNewswire Inc. • 02/12/2025 09:01:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/12/2025 03:59:11 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/21/2025 11:10:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2025 09:15:24 PM
- Bio-Path Holdings Provides 2025 Clinical and Operational Update • GlobeNewswire Inc. • 01/10/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2024 09:30:09 PM
- Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity • GlobeNewswire Inc. • 12/19/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2024 10:16:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2024 09:15:37 PM
- Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients • GlobeNewswire Inc. • 12/11/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/25/2024 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2024 12:30:32 PM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM
VAYK Corrects Major Clerical Error to Report $668K Operating Revenue for 2024 • VAYK • Apr 17, 2025 9:00 AM
UAV Corp Names David Dugas as President and Chief Operating Officer • UMAV • Apr 17, 2025 8:30 AM
Yuengling's Ice Cream Corporation (OTC: YCRM), Doing Business as ReachOut, Files 2024 10-K With Profitability, Growth, and Corporate Transformation in Focus • YCRM • Apr 16, 2025 11:07 AM